Seniors will pay record-high Medicare premiums in 2022 after the FDA approved an Alzheimer’s drug that costs $56,000 over the objections of medical advisors. There is zero evidence that the drug cures or reverses Alzheimer’s. Three experts resigned from an FDA committee over the Alzheimer’s drug approval

Dr. Aaron Kesselheim, one of the experts who resigned, told More Perfect Union, “In my view Aducanumab was the worst FDA approval decision in recent history because this is a drug where there’s no evidence that it works.”

President Biden can act to ensure Medicare premiums don’t skyrocket next year.